Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ribavirin + interferon alpha-2a
- Development stage
- Phase 4
- Lead developer
- Roche
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous
01
Overview
This drug is a combination therapy consisting of ribavirin, a synthetic guanosine nucleoside antiviral agent, and interferon alpha-2a (often in its pegylated form as peginterferon alfa-2a), a recombinant cytokine. The combination is primarily used for the treatment of chronic hepatitis C virus (HCV) infection. Ribavirin inhibits viral RNA synthesis and mRNA capping by acting as a nucleoside analog after intracellular phosphorylation. Interferon alpha-2a binds to type 1 interferon receptors on host cells, activating the JAK/STAT pathway and inducing an innate antiviral response through upregulation of multiple genes involved in immune defense. This dual mechanism targets both viral replication directly (ribavirin) and enhances host immune response against HCV (interferon). The combination was considered first-line therapy before the advent of direct acting antivirals but remains notable for its broad-spectrum antiviral activity[1][4][5][6].
- Other names
- ribavirin and interferon alpha-2aribavirin plus interferon alpha-2aribavirin + peginterferon alfa-2a
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)RdRp (Coronavirus RNA-dependent RNA polymerase)vCE (Viral mRNA capping enzyme)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on ribavirin + interferon alpha-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ribavirin + interferon alpha-2a.